The dilemma of approving antidotes

Toxicology

Volumn 233, Issue 1-3 SPEC. ISS., 2007, Pages 13-19

  Steffen, Christian ^a  

^a FEDERAL INSTITUTE FOR DRUGS AND MEDICAL DEVICES   (Germany)

Author keywords

Antidotes; Dimercaptopropanesulfonic acid; Fomepizole; Methylene blue; Obidoxime; Orphan drugs

Indexed keywords

4 DIMETHYLAMINOPHENOL; ACETYLCYSTEINE; ALCOHOL; AMYL NITRATE; ANTIDOTE; ANTITOXIN; ATROPINE; COBALT EDETATE; DANTROLENE; DEFEROXAMINE; DIAZEPAM; DIGOXIN ANTIBODY F(AB) FRAGMENT; DIMERCAPROL; DIPHENHYDRAMINE; EDETATE CALCIUM DISODIUM; FLUMAZENIL; FOLINIC ACID; GLUCAGON; GLUCONATE CALCIUM; HYDROXOCOBALAMIN; METHIONINE; NALOXONE; NEOSTIGMINE; OXIME DERIVATIVE; PENICILLAMINE; PHENTOLAMINE; PHYSOSTIGMINE; PHYTOMENADIONE; UNINDEXED DRUG; VENOM ANTISERUM;

ARTICLE; DECISION MAKING; DRUG APPROVAL; DRUG LEGISLATION; DRUG RESEARCH; HUMAN; INTOXICATION; NONHUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS;

ANTIDOTES; CLINICAL TRIALS; INFORMED CONSENT; POISONING;

ANIMALIA;

EID: 33947730913     PISSN: 0300483X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tox.2006.11.065     Document Type: Article

References (35)

1. Brent J., McMartin K., Philipps S., Burkhart K., Donovan J., Wells M., and Kulig K. Fomepizole for the treatment of ethylene glycol poisoning. Methylpyrazole for Toxic Alcohols Study Group. N. Engl. J. Med. 340 (1999) 832-838
2. Brent J., McMartin K., Phillips S., Aaron C., and Kulig K. Fomepizole for the treatment of methanol poisoning. N. Engl. J. Med. 344 (2001) 424-429
3. Combemale M. De l'action methémoglobinisant du bleu de méthylene. C. R. Seances Soc. Biol. Fil. 43 (1891) 300-302
4. Council of Europe, 1990. Resolution of the Council and of the Representatives of the Governments of the Member States, meeting within the Council of 3 December 1990 on improving the prevention and treatment of acute human poisoning. Official J. Eur. Commun. C 329, 6-18.
5. Council of Europe, 1997. Convention for the Protection of Human Rights and Dignity of the Human Being with regard to the Application of Biology and Medicine: Convention on Human Rights and Biomedicine. http://conventions.coe.int/treaty/en/html/164.htm ETS no. 164.
6. Council of Europe, 2004. Additional Protocol to the Convention on Human Rights and Biomedicine concerning Biomedical Research (Chapter V, Article 15).
7. EMEA, 2003. EMEA/CPMP Guidance Document on the Use of Medicinal Products for the Treatment of Patients Exposed to Terrorist Attacks with Chemical Agents. EMEA/CPMP/1255/03.
8. EMEA, 2005. CHMP Guideline on Procedures for the Granting of a Marketing Authorisation under Exceptional Circumstances, pursuant to Article 14(8) of Regulation (EC) No. 726/2004.
9. European Commission, 2005. Commission Directive 2005/28/EC of 8 April 2005 laying down principles and detailed guidelines for good clinical practice as regards investigational medicinal products for human use, as well as the requirements for the authorisation of the manufacturing or importation of such products.
10. European Commission, 2006. Commission Staff Working Document on the experience acquired as a result of Regulation (EC) No. 141/2000 on orphan medicinal products and account of the public health benefits obtained. Draft for public consultation, 08.02.2006.
11. Friehoff F., and Lobemann K. Toluidinblau bei der Behandlung der toxischen Hämoglobinämien. Ther. Ggw. 91 (1952) 446-450
12. Haggard H., and Greenberg L. Methylene blue: a synergist, not an antidote, for carbon monoxide. J. Am. Med. Assoc. 100 (1933) 2001-2003
13. ®. Kasuistik mit Übersicht über die Weltliteratur. Inaugural-Dissertation, Universität Kiel.
14. Hauschild F. Untersuchungen über die Wirkung einiger Redox-farbstoffe bei Zuständen gestörter Atmung. Naunyn Schmiedebergs. Arch. Exp. Pathol. Pharmakol. 18 (1936) 1580-1581
15. ICH: International Conference on Harmonisation of technical requirements for registration of pharmaceuticals for human use, 2000. ICH Harmonised Tripartite Guideline: Maintenance of the ICH guideline on non-clinical safety studies for the conduct of human clinical trials for pharmaceuticals M3 (R1).
16. IPCS: The International Programme on Chemical Safety, 2006. Guidelines for poison control. II. Technical guidance-7. Antidotes and their availability.
17. IPCS INCHEM, 2006. http://www.inchem.org/pages/antidote.html. The IPCS/EC Antidote Series are published by Cambridge University Press, Cambridge CB 2 2RU, England.
18. Kiese M., Lörcher W., Weger N., and Zierer A. Comparative studies on the effects of toluidine blue and methylene blue on the reduction of ferrihemoglobin in man and dog. Eur. J. Clin. Pharmacol. 4 (1972) 115-118
19. Liechti M.E., and Kupferschmidt H. Gamma-hydroxybutyrate (GHB) and gamma-butyrolactone (GBL): analysis of overdose cases reported to the Swiss Toxicological Information Centre. Swiss Med. Wkly. 134 (2004) 534-537
20. Quang L.S., Desai M.C., Shannon M.W., Woolf A.D., and Maher T.J. 4-Methylpyrazole decreases 1,4-butanediol toxicity by blocking its in vivo biotransformation to gamma-hydroxybutyric acid. Ann. N. Y. Acad. Sci. 1025 (2004) 528-537
21. Sayn-Wittgenstein-Hohenstein B.z., and Egert J. Bericht des Ausschusses für Jugend, Familie und Gesundheit (13. Ausschuss). Ausschuss für Jugend, Familie und Gesundheit des Deutschen Bundestages. Drucksache 7/5091 (1976) 1-24
22. Rettig, R., 2003. The Food and Drug Administration confronts Homeland and National Security. RAND Corporation occasional paper series (www.rand.com).
23. Rosen P., Johnson C., McGehee W., and Beutler E. Failure of methylene blue treatment in toxic methemoglobinemia. Association with glucose-6-phosphate dehydrogenase deficiency. Ann. Int. Med. 75 (1971) 83-86
24. Singelmann E., Wetzel E., Adler G., and Steffen C. Erythrocyte membrane alterations as the basis of chlorate toxicity. Toxicology 30 (1984) 135-147
25. Steffen C., and Seitz R. Severe chlorate poisoning: report of a case. Arch. Toxicol. 48 (1981) 281-288
26. Steffen C., and Wetzel E. Chlorate poisoning: mechanism of toxicity. Toxicology 84 (1993) 217-231
27. Stenzel, D., 1994. In vitro Untersuchungen zur Beeinflussung der Methämoglobinbildung und damit zusammenhängender Parameter im menschlichen Erythrozyten durch die Phenothiazinfarbstoffe Methylenblau, Toluidinblau und Thionin. Inaugural-Dissertation, Philipps-Universität Marburg.
28. Thiermann H., Mast U., Klimmek R., Eyer P., Hibler A., Pfab R., Felgenhauer N., and Zilker T. Cholinesterase status, pharmacokinetics and laboratory findings during obidoxime therapy in organophosphate poisoned patients. Hum. Exp. Toxicol. 16 (1997) 473-480
29. Thiermann H., Szinicz L., Eyer F., Worek F., Eyer P., Felgenhauer N., and Zilker T. Modern strategies in therapy of organophosphate poisoning. Toxicol. Lett. 107 (1999) 233-239
30. Thiermann H., Szinicz L., Eyer P., Zilker T., and Worek F. Correlation between red blood cell acetylcholinesterase activity and neuromuscular transmission in organophosphate poisoning. Chem. Biol. Interact. 157-158 (2005) 345-347
31. Warburg O., Kubowitz F., and Christian W. Über die katalytische Wirkung von Methylenblau in lebenden Zellen. Biochem. Z. 227 (1930) 245-271
32. Wendel B. The control of methaemoglobinaemia with methylene blue. J. Clin. Invest. 18 (1939) 179-185
33. Williams J., and Challis F. Methylene blue as an antidote for aniline dye poisoning. J. Clin. Lab. Med. 19 (1933) 166-171
34. World Medical Association, 1964, as amended. Ethical Principles for Medical Research Involving Humans Subjects (Declaration of Helsinki). Paragraph 26.
35. Zvosec D.L., Smith S.W., McCutcheon J.R., Spillane J., Hall B.J., and Peacock E.A. Adverse events, including death, associated with the use of 1,4-butanediol. N. Engl. J. Med. 344 (2001) 87-94